SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is trending as it hits new all-time highs, driven by optimism around its prediction markets business and upcoming S&P 500 inclusion. The community is actively discussing the stock's strong performance and potential for further growth, with some speculating about future price targets. Bullish sentiment is fueled by the expectation of increased trading volumes and potential benefits from new product offerings.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after a significant drop following mixed Phase 3 trial results, specifically related to high placebo response impacting statistical significance. The conversation centers on whether the sell-off is an overreaction given the company's cash reserves and ongoing pipeline, with some speculating about a potential buyout and others wary of the mixed data. Community members are actively discussing dip-buying strategies, potential bounce-back scenarios, and comparisons to competitor performance.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp drop in stock price following remarks made by a former FDA official, George Tidmarsh, regarding the drug Voclosporin. The community is expressing concerns about the validity and timing of the statement, with some suspecting market manipulation and questioning the company's leadership response. The drop has also impacted buyout hopes.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as investors anticipate the release of its preliminary feasibility study (PFS), with community members expressing excitement and speculating about potential partnerships and government support. Bullish sentiment is fueled by the company's strategic positioning in lithium extraction and battery recycling, as well as recent revenue gains. Some investors are drawing parallels to other successful stocks in the sector, while cautioning about potential short squeezes and profit-taking.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to a video posted by Trump discussing the medical benefits of CBD for seniors, sparking community discussion around potential rescheduling.  Traders are actively weighing the implications of potential policy changes and the sector's volatile nature, while some highlight positive movement in European cannabis markets. The community speculates on the timing and impact of any official announcements.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending, sparking community engagement around the classic 'What's UpDog?' joke. Built on Solana and listed on Jupiter, the community emphasizes its longevity and strong holder base. The conversation also highlights the accessibility of becoming an $UPDOG millionaire.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending due to speculation around a potential gamma squeeze and significant price movement, leading to community discussions about float size and potential price targets. Some traders are pointing to technical indicators and chart patterns, while others caution about the risks associated with Chinese stocks and potential pump-and-dump schemes. The stock's volatility and history of reverse splits are also prominent points of discussion among investors.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as investors react to news of the company's integration with OpenAI's ChatGPT, enabling instant checkout for goods from Shopify merchants. Community members are discussing the potential for a significant boost to SHOP's revenue as a result of this integration, and some see the e-commerce sector heating up. Technical analysts point to a potential breakout coil forming, while others caution about overbought conditions.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt Holdings is trending due to renewed interest following news of a new board appointment, sparking discussions about the company's potential growth strategy within the digital asset space. The community is actively speculating about the impact of new leadership and potential partnerships, especially regarding expansion into foreign markets and web3 technologies. Bullish sentiment is building around the possibility of a short squeeze and the company's strengthened financial position after debt reduction.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following news of a partnership with Google to enhance AI-powered shopping experiences. While some investors are excited about the potential growth, others express frustration with the stock's historical underperformance and question whether the partnership will provide an immediate catalyst. Community members are debating whether this is a turning point or another false start for the fintech giant.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

Equity

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 


Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, in combination with Tirzepatide, helped preserve lean mass during Tirzepatide-induced weight loss in a mid-stage study.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-positive-phase-2-embraze-trial-results">trial</a> demonstrated that 30% of the total weight loss with Tirzepatide alone was due to lean mass loss. Tirzepatide is the active ingredient in Eli Lilly's weight loss therapy Zepbound.Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.Reduction in body weight, however, was marginally higher in patients who received Tirzepatide alone.No subjects experienced serious adverse events or discontinuations considered to be related to apitegromab treatment, and there were no deaths, the company added.Akshay Vaishnaw, President of R&amp;D, Scholar Rock, said that while therapies like Tirzepatide have been an effective innovation for people with obesity, they result in substantial loss of lean muscle mass for patients, leading to unwanted health risks.Vaishnaw added that the company is focused on preparing for the launch of Apitegromab and, following its potential approval for spinal muscular atrophy, looks forward to studying it in a range of neuromuscular diseases with high unmet needs.Approval for Apitegromab in spinal muscular atrophy is expected by late September.Scholar Rock is not alone in attempting to preserve lean mass during drug-induced weight loss. Earlier this month, Regeneron (REGN) said that a mid-stage trial demonstrated that approximately 35% of Semaglutide-induced weight loss was due to loss of lean mass. However, combining Semaglutide, the active ingredient in Novo Nordisk’s weight loss drug Wegovy, with Regeneron’s Trevogrumab with or without Garetosmab helped preserve lean mass while increasing loss of fat mass, the company said.On Stocktwits, retail sentiment around Scholar Rock jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_1_49_41_PM_png_73aabfb93c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, noted that the lack of increased weight loss with the combination compared to Tirzepatide alone is bearish.<stembedurl>https://stocktwits.com/BioLong123/message/618251994</stembedurl><a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> is down by 18% this year but up by over 320% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/coinbase-circle-pop-as-stablecoin-legislation-clears-senate/chlsfGnRR2K">Coinbase, Circle Pop As Stablecoin Legislation Clears Senate – But These Two Stocks Took A Hit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” takeover potential.Jefferies thinks big pharma companies are "still on the hunt" for deals as Pfizer (PFE), Biogen (BIIB), Merck (MRK), Eli Lilly (LLY), Gilead (GILD), and others have publicly discussed active business development to "fill voids."Jefferies named South San Francisco-based Akero among the names it believes hold promise, alongside Scholar Rock (SRRK).The firm noted that Akero has potential sales of $2 billion to $3 billion and "clean and strong" Phase II data of its lead product candidate, Efruxifermin, in patients with non-alcoholic Steatohepatitis.As for Scholar Rock (SRRK), Jefferies deems it a promising target with likely approval for its investigational treatment Apitegromab in spinal muscular atrophy by late September.The company’s upcoming mid-stage trial data of Apitegromab in obesity "could be a clearing event" that could help simplify the stock's valuation, it added.On Stocktwits, retail sentiment around Akero stayed within ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:625/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_36_24_PM_png_6b185bcea0.webp" alt="AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="625" height="66"><figcaption>AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, all 11 analysts covering AKRO rate it a ‘Buy’ or higher. The stock has an average price target of $76.30.Meanwhile, retail sentiment around SRRK stayed ‘bearish’ over the last 24 hours while message volume took a dip from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:633/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_37_19_PM_png_cb246dfd4a.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="633" height="65"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> All of the 10 analysts covering SRRK also rate it ‘Buy’ or higher, with an average price target of $49.67.While <a href="https://stocktwits.com/symbol/AKRO">AKRO</a> has nearly doubled its value this year, <a href="https://stocktwits.com/symbol/SRRK">SRRK</a> is down by over 25%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/merck-gets-fda-approval-for-keytruda-in-more-head-and-neck-cancer-patients/chliQJzRRbZ">Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mergers and Acquisitions message in neon lights. (Image Courtesy: Getty Images)

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased

Jefferies thinks big pharma companies are "still on the hunt" for deals. 

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases...

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious...

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRRK News

SRRK Scholar Rock Holding Corp